Anika Therapeutics (ANIK) EBT (2010 - 2026)

Anika Therapeutics (ANIK) has reported EBT for 17 consecutive years, with $3.4 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBT rose 185.22% year-over-year to $3.4 million in Q2 2026; TTM through Jun 2026 was -$3.9 million, a 56.14% increase from a year earlier, with the FY2025 full-year figure at -$10.2 million, down 151.28% from the prior year.
• EBT was $3.4 million for Q2 2026 at Anika Therapeutics, up from -$4.8 million in the prior quarter.
• Over five years, EBT peaked at $25.3 million in Q4 2023 and troughed at -$12.0 million in Q1 2023.
• A 5-year average of -$460333.3 and a median of -$2.7 million in 2023 frame the typical range for EBT.
• Across the five-year window, EBT jumped 351.15% in 2022 and tumbled 788.0% in 2025, its largest moves.
• Over 5 years, EBT stood at $16.7 million in 2022, then surged by 51.56% to $25.3 million in 2023, then tumbled by 105.04% to -$1.3 million in 2024, then jumped by 86.2% to -$176000.0 in 2025, then surged by 2020.45% to $3.4 million in 2026.
• The last three EBT figures came in at $3.4 million (Q2 2026), -$4.8 million (Q1 2026), and -$176000.0 (Q4 2025), per Business Quant data.